Liquid Biopsy: Recent Advances in the Detection of Circulating Tumor Cells and Their Clinical Applications

2020 ◽  
pp. 43-66 ◽  
Author(s):  
Ruth L. Katz ◽  
Tanweer M. Zaidi ◽  
Xiaohui Ni
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Clinical Applications ◽  
Recent Advances

Recent advances in microfluidic technologies for circulating tumor cells: enrichment, single-cell analysis, and liquid biopsy for clinical applications

Lab on a Chip ◽  
2020 ◽  
Vol 20 (21) ◽  
pp. 3854-3875 ◽  
Author(s):  
Haimeng Pei ◽  
Lu Li ◽  
Zhaojun Han ◽  
Yiguo Wang ◽  
Bo Tang
Keyword(s):  
Single Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Single Cell Analysis ◽  
Clinical Applications ◽  
Cell Analysis ◽  
Recent Advances

Microfluidic technologies for circulating tumor cells: from enrichment to single-cell analysis to liquid biopsy for clinical applications.

Liquid biopsy: novel technologies and clinical applications

2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Natalie Reimers ◽  
Klaus Pantel
Keyword(s):  
Cancer Patients ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Liquid Biopsy ◽  
Clinical Applications ◽  
Novel Technologies ◽  
The Past

Abstract“Liquid biopsy” was introduced as a new diagnostic concept in 2010 for the analysis of circulating tumor cells (CTCs) and has been now extended to material (in particular DNA) released by tumor cells in the peripheral blood of cancer patients. Over the past decade, various methods have been developed to detect CTCs and ctDNA in the peripheral blood of cancer patients.

scholarly journals Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer

2020 ◽  
Vol 10 (11) ◽  
pp. 3704
Author(s):  
Menno Tamminga ◽  
Harry J.M. Groen
Keyword(s):  
Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Patient Characteristics ◽  
Clinical Applications ◽  
Liquid Biopsies ◽  
Improved Outcomes ◽  
Tumor Material

As therapies have become more and more dependent on tumor as well as patient characteristics, obtaining tumor material has become of great importance. Liquid biopsies hold much potential as shown by a large amount of evidence across several studies. Clinical applications for circulating tumor cells (CTCs) are unfortunately still lacking. In part this is due to a lack of studies comparing liquid biopsies to conventional diagnostics and response measurements as well as studies showing that liquid biopsies can be used to switch therapies leading to improved outcomes. However, liquid biopsies using ctDNA for specific markers such as EGFR, ALK, ROS1 or RET have clinical applications because specific drugs are available.

Sign in / Sign up

Export Citation Format

Share Document